Hassan Serhan, Ph.D., and Jacob Einhorn, two experts with deep roots in the orthopedic arena, are the newest members of Albany, New York-based ReVivo Medical’s Board of Advisors.
Serhan and Einhorn Join ReVivo’s Advisory Board
2 min read Premium comments
Secondary#garymittleman#hassanserhan#jacobeinhorn#revivomedical
Hassan Serhan, Ph.D. is the former Distinguished Engineering Fellow, Senior Director, Research & Technology, at DePuy Synthes Spine. While at the J & J company, Dr. Serhan headed up spine and orthopedics, as well as technology evaluation and development.
“It is very exciting to be part of a new venture that has a disruptive technology in an otherwise ‘me too’ market segment,” said Dr. Serhan to OTW. “ReVivo’s dynamic interbody fusion devices and the innovative cervical plating system represent the next generation cervical fusion devices.”
Jacob Einhorn, chief technology officer and co-founder at Intrinsic Therapeutics, Inc. has over 20 years of experience creating new technologies—primarily focused on spine. While at Stryker and Pfizer, Einhorn has headed up clinical development, commercial marketing, new product development, R&D and regulatory strategy.
Jacob Einhorn commented to OTW, “While motion preservation devices grab a lot of the cervical discectomy attention, the largest (and still growing) segment by far is fusion. ReVivo’s innovative implant designs incorporate unique features that are based on leading-edge science and provide a real competitive advantage in this growing area.”
“Our current management team is well versed to create new medical devices, develop prototypes, have them tested and conduct clinical trials. Now, as we prepare to start our clinical trial, we wish to make sure that we are positioning ourselves for what comes later: the commercial arena,” noted company President and CEO Gary Mittleman. “Thus, we have appointed to our Board of Advisors two individuals with a wealth of new product development experience in the medical orthopaedic and spine device space.”
Initially, Dr. Serhan and Einhorn will serve as advisors in the company’s clinical trial design that will ultimately enhance the value of ReVivo Medical as an acquisition candidate.
ReVivo Medical plans to begin recruiting for its 50-patient clinical study in late Q2 2021. In this trial, scheduled to take place at the Albany Medical Center and Cleveland Clinic, participants will receive ReVivo Medical’s next generation design anterior cervical plate and interbody cages used in anterior cervical discectomy and fusion procedures.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.